Reuters | |

(Reuters) - Mylan NV on Thursday lowered the top-end of its full-year sales estimate, saying a recovery of demand for its non-coronavirus related medicines would take until at least the end of the year, sending its shares down as much as 3.5%.

Generic drugmakers like Mylan benefited in the first quarter from customers stocking up on over-the-counter medicines ahead of the lockdowns imposed to curb the spread of the virus.

The stockpiling, however, meant that patients bough...

Reuters | |

(Reuters) - Bristol Myers Squibb Co raised its annual profit forecast on Thursday on hopes of a recovery in sales of its hospital-administered drugs, which had taken a hit as patients stayed away from doctors’ offices due to the COVID-19 pandemic.

The U.S. drugmaker said it was expecting demand for its drugs from new patients as well as for its products administered by doctors to recover in the third quarter and stabilize in the fourth quarter.

Pfizer and Merck & Co ...

Michael McTague | |

The race to find a coronavirus vaccine puts the pharmaceutical industry in the spotlight. Politicians who criticized companies that launch medical breakthroughs for making money are hoping that one of them will come up with a vaccine to put the deadly virus behind us. Able Global Partners has been in the forefront of investing in numerous Contract Development Manufacturing Organizations (CDMOs) and understands their significance. A number of comp...